Columbia Hospital"With the June sale of 4 million shares...


October 23, 1991|By Opinions on stocks offered by investment experts.Compiled by Steve Halpern for Knight Ridder

Columbia Hospital

"With the June sale of 4 million shares to the public, Columbia Hospital (CHOS, OTC, around $15) has built a war chest of $100 million to buy and revitalize under-performing hospitals," says the Insider's Chronicle of Bethesda.

"Earnings for the three months ended last June were up 70 percent; revenues for the period doubled. Chairman Richard Scott and Richard Rainwater hold 67 percent of the shares. Two insiders, including the president, purchased 4,000 shares at the 13 to 13 1/2 level."


"We have added Frenchtex (FRCH, OTC, around $6) to our recommended list for aggressive investors seeking significant capital gains," says the Brous Report of Great Neck, N.Y.

"The stock is currently down over 30 percent from its high. We believe the decline is temporary and that the shares are substantially undervalued. We look for fiscal 1992 earnings to reach $1 per share vs. an estimated 6 cent a share loss for fiscal 1991. Our initial price target for the stock is $10 a share. We recommend purchase."

Carnival Cruise

"We asked our research analysts to isolate their favorite stocks -- those which they considered especially attractive in today's market. One favorite was Carnival Cruise (CCL, AMEX, around $27), the world's largest cruise line operator, a company that has run into some choppy seas in recent years," says United & Babson Investment Report of Wellesley Hills, Mass.

"The expected elimination of the Crystal Palace, which has been a drain on profits, could lead to earnings gains of 30 to 50 percent in the next few quarters. The stock is a buy."

G.T. Global

"G.T. Global Health Care may cast its net around the world, but most of its fish are caught at home," says Morningstar Mutual Funds of Chicago.

"Only about one quarter of invested assets are in foreign companies; the remaining 75 percent is devoted to American firms. When manager Ted Gomoll does invest abroad, his holdings tend to be either pharmaceutical companies or conglomerates with large pharmaceutical businesses. Overall, the fund looks like a fine long-term prospect."

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.